This company is no longer in business. Investors can get details about any potential exits or failures here.

NowRx

[Closed for Investment] NowRx, with a pre-money valuation of $65 million, is raising funds on SeedInvest through Reg A+ crowdfunding. It is a pharmacy delivery solution that uses advanced technology to provide free same-day delivery for all prescription needs. The on-demand delivery model of NowRx offers convenience, higher worker productivity, and superior customer experience. NowRx was founded by Cary Breese and Sumeet Shoekand and has raised over $10 million in previous rounds of financing. The current funding round has a minimum target of $1,500,000 and a maximum target of $20,000,001, and the funds will be used for marketing and sales, R&D and technology development, and expansion. NowRx has reported 1064% customer growth since 2016 and a 30% revenue run rate growth in five months.

Expand

Investment Overview

Raised this Round: Raised: $20,002,878

Deal Terms

Total Commitments ($USD)

Platform
SeedInvest
Start Date
08/14/2019
Close Date
06/19/2020
Min. Goal
$1,500,000
Max. Goal
$20,000,001
Min. Investment

$1,000

Security Type

Equity - Preferred

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$3.45

Pre-Money Valuation

$65,000,000

Company & Team

Company

Year Founded
2015
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Location
Mountain View, California
Company Website
Visit Website

Team

Employees
25

Financials

Financials are not currently available for this company. This may occur if the company is still Testing the Waters, is a Regulation D offering, or if the financials are still under review and being confirmed by our team. For Reg CF and Reg A+ raises, please check back later.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Analyst Report Analyst Report Methodology Article

Summary

NowRX has been selected as a “Top Deal” by KingsCrowd. Today, we are reiterating this Top Deal rating, reserved for the top 10% of all deals across the market. If you have questions regarding our deal diligence and selection methodology please reach out to [email protected].

Next Section: Other

Since We Last Saw NowRx...

NowRx, a technology-driven, on-demand pharmacy, was rated a Top Deal by Kingscrowd in May of 2018. The team is now raising its Series B round as a Regulation A offer on SeedInvest with the ultimate goal of developing AI-powered robotic technology for free, same-day delivery of both prescription and over-the-counter (OTC) medications. In doing so, the team aims to eliminate the need for pharmacies altogether, heavily disrupting the $313B pharmaceutical market

Next Section: Other

NowRx Financials Update

In March of 2018, NowRx closed its seed round at $1,345,000 on convertible note with a $10M valuation cap. Its series A closed in August of the same year at $6,796,700 in preferred equity with a $20M pre-money valuation. The current campaign offers preferred equity at a pre-money valuation of $65M.

NowRx revenues for 2018 were $4.7M, nearly a 90% increase from the previous year. Gross profit for 2018 was $634K, compared to $334K in 2017. With an increase in revenue from 2017 to 2018 also came an increase in total operating expenses, which stood at $1.3M and $3.5M, respectively. 

As of July 2019, revenue stands at $7.2M. To date, NowRx has filled over 100k prescriptions. Though the valuation has gone up significantly, this significant increase in revenue and proven traction derisks the investment.

Next Section: Other

Why We (Continue To) Like It

 

 

 

  • Growth Plans: As of now, NowRx serves only the Bay area, making geographic expansion a natural next step in scaling. By 2023, NowRx plans to expand to 20 territories. This expansion will begin in the Los Angeles and Orange County areas and later move up and down the west coast with the ultimate goal of having 5-10 locations per metropolitan area. The team anticipates a 3x growth rate in its already established Bay Area base with the addition of these new locations due to the ramping up of customer marketing and sales efforts.

Since its last raise, NowRx has significantly sped up growth in the Bay Area where it was originally established. With each funding round, customer acquisition has increased. In addition, the team has opened two licensed micro-fulfilment centers in the Bay Area. A third facility in Orange County has also been leased. Retention rates are also high, with 86% of users claiming that it is “extremely likely” that they will use NowRx again. High satisfaction rate ground proof-of-concept before continuing geographic expansion.

 

 

  • Data Aggregation: As with any machine-learning algorithm, the more data the better. NowRx has already acquired a substantial amount of customer data to better its systems. Efficiency and accuracy of these algorithms can only improve with more data. Not to mention, a large database could prove to be quite valuable in the event of a future acquisition, upping price point and overall value of the company.

 

 

 

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
05/20/2022 SeedInvest $275,000,000 $30,006,323 Equity - Preferred Funded RegA+
10/05/2021 SeedInvest $275,000,000 $3,635,310 Equity - Preferred Funded Test the Waters / RegA+
06/19/2020 SeedInvest $65,000,000 $20,002,878 Equity - Preferred Funded RegA+
06/30/2018 SeedInvest $20,000,000 - Equity - Preferred Funded RegA+
07/19/2017 SeedInvest $6,000,000 $209,230 Convertible Note Funded RegCF / RegD 506(c)
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
NowRx on SeedInvest
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $65,000,000
Price per Share: $3.45

Follow company

Follow NowRx on SeedInvest

Buy NowRx's Deal Report

Warning: according to the close date for this deal, NowRx may no longer be accepting investments.

NowRx Deal Report

Get Kingscrowd's comprehensive report on NowRx including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NowRx is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the NowRx deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge